Citations

Clear

3138 citation(s) found for "Smith, AM".

A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts
Wald, Abigail I. , Spagnolo, Daniel M. , Grupillo, Maria, Lai, Yi-Tak, O’Broin-Lennon, Anne Marie, Park, Walter G. , Pfau, Patrick , Kubiliun, Nisa , Easler, Jeffrey J. , Dam, Aamir, Mok, Shaffer , Wallace, Michael B. , Kumbhari, Vivek , Marsh, Wallis, Thakkar, Shyam , Fairley, Kimberly, Bhat, Yasser M., Nasr, John , Khalid, Asif , Fasanella, Kenneth, Chennat, Jennifer, Singh, Harkirat , Sarkaria, Savreet, Slivka, Adam, Gabbert, Charles, Sawas, Tarek , Tielleman, Thomas , Vanderveldt, Hendrikus Dutch, Tavakkoli, Anna , Smith, Katelyn, Hruban, Ralph H. , Paniccia, Alessandro , Zureikat, Amer H., Lee, Kenneth K. , Ongchin, Melanie , Zeh, Herbert J. , Minter, Rebecca M., He, Jin , Wallace, Michael B , Nikiforova, Marina N. , Melan, Melissa A. , Brand, Randall E. , McGrath, Kevin , Polanco, Patricio Marcelo , DeWitt, John M. , Boone, Brian A. , Afghani, Elham , Ramrakhiani, Sanjay , Skef, Wasseem , Thiruvengadam, Nikhil Ravi , Das, Rohit Kumar , Smith, Lynette M. , Bell, Phoenix , Nikiforov, Yuri E. , Singhi, Aatur Dilip

Mayo Clinic

Annals of Surgery | May 22, 2023 | Volume: 278 | Issue: 4 | Pages: e789-e797

10.1097/sla.0000000000005904 | PMID 37212422 Get It

Objective: We report the development and validation of a combined DNA/RNA next-generation sequencing (NGS) platform to improve the evaluation of pancreatic cysts. Background and Aims: Despite a multidisciplinary approach, pancreatic cyst classification, such as a cystic precursor neoplasm, and the detection of high-grade dysplasia and early adenocarcinoma (advanced neoplasia) can be challenging. NGS of preoperative pancreatic cyst fluid improves the clinical evaluation of pancreatic cysts, but the recent identification of novel genomic alterations necessitates the creation of a comprehensive panel and the development of a genomic classifier to integrate the complex molecular results. Methods: An updated and unique 74-gene DNA/RNA-targeted NGS panel (PancreaSeq Genomic Classifier) was created to evaluate 5 classes of genomic alterations to include gene mutations (e.g., KRAS, GNAS, etc.), gene fusions and gene expression. Further, CEA mRNA (CEACAM5) was integrated into the assay using RT-qPCR. Separate multi-institutional cohorts for training (n=108) and validation (n=77) were tested, and diagnostic performance was compared to clinical, imaging, cytopathologic, and guideline data. Results: Upon creation of a genomic classifier system, PancreaSeq GC yielded a 95% sensitivity and 100% specificity for a cystic precursor neoplasm, and the sensitivity and specificity for advanced neoplasia were 82% and 100%, respectively. Associated symptoms, cyst size, duct dilatation, a mural nodule, increasing cyst size, and malignant cytopathology had lower sensitivities (41–59%) and lower specificities (56–96%) for advanced neoplasia. This test also increased the sensitivity of current pancreatic cyst guidelines (IAP/Fukuoka and AGA) by >10% and maintained their inherent specificity. Conclusions: PancreaSeq GC was not only accurate in predicting pancreatic cyst type and advanced neoplasia but also improved the sensitivity of current pancreatic cyst guidelines.
(510) Do Patients with Peyronie’s Disease Perceive Penile Curvature Differently than the General Population?
Lui, Jeffrey Frederico , Ziegelmann, M., Breyer, B, Smith, Ryan P. , Yeaman, Clinton , Kern, N, Henry, A, Lui, J

Mayo Clinic

The Journal of Sexual Medicine | May 22, 2023 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdad060.480 Get It

Abstract Introduction Perception of penile curvature (PC) varies widely, and correction of PC is in the eye of the beholder. Objective We sought to investigate if patients with Peyronie’s Disease (PD) had differing opinions on correction of PC compared to general andrology (AD) patients without PD and general urology (URO) patients. Methods A cross-sectional survey was administered to adult patients in andrology and general urology clinics at 3 geographically separate institutions. Patients were grouped with having PD vs AD vs URO conditions. The survey consisted of unlabeled images of penis models with varying degrees of PC (range 10-90°). Respondents were asked to select the images they would want surgically corrected. Univariable and multivariable analyses were performed to identify demographic variables associated with willingness to consider correction. Results Ninety-four PD, 106 AD, and 302 URO patients were recruited. When comparing the 3 groups, besides obvious gender differences with PD patients, PD patients were less in 25-34 age range and more in 55-64 age range (p=0.01 and p=0.007). PD was less represented in Mid-Atlantic (p<0.001). 8% of PD, 12% of AD, and 20% of URO patients chose not to surgically correct any degree of PC (p=0.001). Among those who endorsed willingness to surgically correct PC, the average threshold for correction was 52.5° (SD 13) for PD, 37.2° (SD 29.5) for AD, and 51.0° (SD 19.9) for URO patients. When comparing PD patients with AD patients, no difference in the decision to surgically correct was found (p=0.42). This was also found to be the case when comparing PD with URO (p=0.46) and PD+AD patients vs URO (p=0.67). On univariable analysis, among AD patients, those ages 55-64 were more willing to undergo PC correction at lower degrees of PC (p=0.03) but did not hold up on multivariable analysis (p=0.40). No other demographic factors among PD and AD groups were found to have an impact on willingness to undergo PC correction (Table 1). Conclusions No significant differences were seen in the decision to surgically correct PC when comparing the perspectives of patients with PD, AD, and URO. Roughly 10% of all of these patients would defer on surgical management of any degree of PC. Despite having PC, no demographic differences were seen among PD patients’ willingness to correct PC. Disclosure No
Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder
Yetmar, Zachary A. , Duffy, Dustin, Smith, Byron H. , Vikram, Holenarasipur R. , Brumble, Lisa , Beam, Elena , Beam, Elena , Vikram, Holenarasipur R. , Yetmar, Zachary A , Smith, Byron , Limper, Andrew H.

Mayo Clinic

Clinical Transplantation | May 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/ctr.15021 | PMID 37195184 Get It

Stimulation to probe, excite, and inhibit the epileptic brain
Frauscher, Birgit , Bartoloméi, Fabrice , Baud, Maxime O. , Smith, Rachel J. , Worrell, Gregory A. , Lundstrom, Brian N. , Worrell, Gregory A , Lundstrom, Brian Nils , Frauscher, Birgit , Baud, Maxime O

Mayo Clinic

Epilepsia | May 17, 2023 | Volume: 64 | Issue: S3 | Pages: No page available

10.1111/epi.17640 | PMID 37194746 Get It

AbstractDirect cortical stimulation has been applied in epilepsy for nearly a century and has experienced a renaissance, given unprecedented opportunities to probe, excite, and inhibit the human brain. Evidence suggests stimulation can increase diagnostic and therapeutic utility in patients with drug‐resistant epilepsies. However, choosing appropriate stimulation parameters is not a trivial issue, and is further complicated by epilepsy being characterized by complex brain state dynamics. In this article derived from discussions at the ICTALS 2022 Conference (International Conference on Technology and Analysis for Seizures), we succinctly review the literature on cortical stimulation applied acutely and chronically to the epileptic brain for localization, monitoring, and therapeutic purposes. In particular, we discuss how stimulation is used to probe brain excitability, discuss evidence on the usefulness of stimulation to trigger and stop seizures, review therapeutic applications of stimulation, and finally discuss how stimulation parameters are impacted by brain dynamics. Although research has advanced considerably over the past decade, there are still significant hurdles to optimizing use of this technique. For example, it remains unclear to what extent short timescale diagnostic biomarkers can predict long‐term outcomes and to what extent these biomarkers add information to already existing biomarkers from passive electroencephalographic recordings. Further questions include the extent to which closed loop stimulation offers advantages over open loop stimulation, what the optimal closed loop timescales may be, and whether biomarker‐informed stimulation can lead to seizure freedom. The ultimate goal of bioelectronic medicine remains not just to stop seizures but rather to cure epilepsy and its comorbidities.
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Veeraraghavan, Jamunarani , Gutiérrez, Carolina , Angelis, Carmine De , Davis, Robert , Wang, Tao , Pascual, Tomás , Selenica, Pier , Sanchez, Katherine , Nitta, Hiroaki , Kapadia, Monesh , Pavlick, Anne C. , Rexer, Brent N. , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Weigelt, Britta , Prat, Aleix , Osborne, C. Kent , Rimawi, Mothaffar F. , De Angelis, Carmine , Galvan, Patricia , Rexer, Brent , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna M , Krop, Ian E , Goetz, Matthew P , Nangia, Julie R , Wolff, Antonio C , Weigelt, Britta , Reis-Filho, Jorge S , Hilsenbeck, Susan Galloway , Prat, Aleix , Osborne, C Kent , Schiff, Rachel , Rimawi, Mothaffar , Wang, Tao , Goetz, Matthew P. , Wolff, Antonio C. , Reis‐Filho, Jorge S. , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | May 17, 2023 | Volume: 29 | Issue: 16 | Pages: 3101-3109

10.1158/1078-0432.ccr-22-3753 | PMID 37195235 Get It

Abstract Purpose: Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier can identify patients with HER2-“addicted” tumors who may benefit from a chemotherapy-sparing strategy. Experimental Design: Baseline HER2+ breast cancer specimens from the TBCRC023 and PAMELA trials, which included neoadjuvant treatment with lapatinib and trastuzumab, were used. In the case of estrogen receptor–positive (ER+) tumors, endocrine therapy was also administered. HER2 protein and gene amplification (ratio), HER2-enriched (HER2-E), and PIK3CA mutation status were assessed by dual gene protein assay (GPA), research-based PAM50, and targeted DNA-sequencing. GPA cutoffs and classifier of response were constructed in TBCRC023 using a decision tree algorithm, then validated in PAMELA. Results: In TBCRC023, 72 breast cancer specimens had GPA, PAM50, and sequencing data, of which 15 had pCR. Recursive partitioning identified cutoffs of HER2 ratio ≥ 4.6 and %3+ IHC staining ≥ 97.5%. With PAM50 and sequencing data, the model added HER2-E and PIK3CA wild-type (WT). For clinical implementation, the classifier was locked as HER2 ratio ≥ 4.5, %3+ IHC staining ≥ 90%, and PIK3CA-WT and HER2-E, yielding 55% and 94% positive (PPV) and negative (NPV) predictive values, respectively. Independent validation using 44 PAMELA cases with all three biomarkers yielded 47% PPV and 82% NPV. Importantly, our classifier's high NPV signifies its strength in accurately identifying patients who may not be good candidates for treatment deescalation. Conclusions: Our multiparameter classifier differentially identifies patients who may benefit from HER2-targeted therapy alone from those who need chemotherapy and predicts pCR to anti-HER2 therapy alone comparable with chemotherapy plus dual anti-HER2 therapy in unselected patients.
Presyncope and Ophthalmoparesis Due to Intracranial Erdheim-Chester Disease
Schipani, Elke , Oakley, Carlee I. , Smith, Kelsey M. , Schipani Bailey, Elke , Smith, Kelsey M , Oakley, Carlee I.

Mayo Clinic

The Neurohospitalist | May 17, 2023 | Volume: 13 | Issue: 3 | Pages: 323-324

10.1177/19418744231168501 | PMID 37441221 Get It

Introduction: An 82-year-old female presented to the emergency department with presyncope and was found to be bradycardic with proptosis and ophthalmoparesis. MRI revealed an extra-axial enhancing mass compressing the medulla and bilateral enhancing retro-orbital masses. Case Description: Imaging, including nuclear medicine bone scan, PET CT, and cardiac MRI raised the suspicion for a histiocytic neoplasm. These findings, along with a fibrohistiocytic infiltrate on bone biopsy and a BRAF V600E oncogenic mutation on plasma cell-free DNA confirmed a diagnosis of Erdheim-Chester disease. Discussion: These enhancing masses invoke a broad differential, including a histiocytic or granulomatous process, fungal infection, amyloidosis, IgG4 disease, and lymphoma. Systematic laboratory, radiologic, pathology, and genetic testing yielded a diagnosis of this rare histiocytic disorder with frequent neurologic involvement.
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac, Adam , Landsburg, Daniel J. , Hughes, Mitchell E. , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie , Stepanovic, Adam , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Farooq, Umar , Saad, Mahak, Evens, Andrew M. , Pandya, Karan, Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Oh, Timothy S. , Nutsch, Heather, Rubinstein, P , Chaudhry, Amina, Zayac, Adam S , Medeiros, L Jeffrey , Kurt, Habibe , Torka, Pallawi , Sundaram, Suchitra , Smith, Stephen D , Naresh, Kikkeri N , Karimi, Yasmin H , Epperla, Narendranath , Bond, David A , Farooq, Umar , Evens, Andrew M , Naik, Seema G , Kamdar, Manali , Haverkos, Bradley M , Karmali, Reem , Oh, Timothy S , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Landsburg, Daniel J , Hu, Marie , Li, Shaoying , Girton, Mark , Medeiros, L. Jeffrey , Kurt, Habibe , Epperla, Narendranath , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | May 12, 2023 | Volume: 7 | Issue: 21 | Pages: 6381-6394

10.1182/bloodadvances.2023009731 | PMID 37171397 Get It

Abstract In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.
Risk factors and prophylaxis for nocardiosis in solid organ transplant recipients: A nested case‐control study
Yetmar, Zachary A. , Chesdachai, Supavit , Duffy, Dustin, Smith, Byron H. , Seville, Maria Teresa , Bosch, Wendelyn , Beam, Elena , Challener, Douglas W. , Beam, Elena , Yetmar, Zachary A , Smith, Byron , Chesdachai, Supavit

Mayo Clinic

Clinical Transplantation | May 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/ctr.15016 | PMID 37170686 Get It

J‐Difference editing (MEGA) of lactate in the human brain at 3T
Robison, Ryan K. , Haynes, Justin R., Ganji, Sandeep , Nockowski, Charles P., Kovács, Zoltán , Morgan, Victoria L. , Smith, Seth A., Thompson, Reid C., Gore, John C. , Choi, Changho , Ganji, Sandeep K, Choi, Changho , Morgan, Victoria L , Ganji, Sandeep K , Pham, Wellington N. , Omary, Reed A.

Mayo Clinic

Magnetic Resonance in Medicine | May 8, 2023 | Volume: 90 | Issue: 3 | Pages: 852-862

10.1002/mrm.29693 | PMID 37154389 Get It

PurposeThe need to detect and quantify brain lactate accurately by MRS has stimulated the development of editing sequences based on J coupling effects. In J‐difference editing of lactate, threonine can be co‐edited and it contaminates lactate estimates due to the spectral proximity of the coupling partners of their methyl protons. We therefore implemented narrow‐band editing 180° pulses (E180) in MEGA‐PRESS acquisitions to resolve separately the 1.3‐ppm resonances of lactate and threonine.MethodsTwo 45.3‐ms rectangular E180 pulses, which had negligible effects 0.15‐ppm away from the carrier frequency, were implemented in a MEGA‐PRESS sequence with TE 139 ms. Three acquisitions were designed to selectively edit lactate and threonine, in which the E180 pulses were tuned to 4.1 ppm, 4.25 ppm, and a frequency far off resonance. Editing performance was validated with numerical analyses and acquisitions from phantoms. The narrow‐band E180 MEGA and another MEGA‐PRESS sequence with broad‐band E180 pulses were evaluated in six healthy subjects.ResultsThe 45.3‐ms E180 MEGA offered a difference‐edited lactate signal with lower intensity and reduced contamination from threonine compared to the broad‐band E180 MEGA. The 45.3 ms E180 pulse had MEGA editing effects over a frequency range larger than seen in the singlet‐resonance inversion profile. Lactate and threonine in healthy brain were both estimated to be 0.4 ± 0.1 mM, with reference to N‐acetylaspartate at 12 mM.ConclusionNarrow‐band E180 MEGA editing minimizes threonine contamination of lactate spectra and may improve the ability to detect modest changes in lactate levels.